Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer

Theranostics. 2021 Jan 1;11(5):2182-2200. doi: 10.7150/thno.53102. eCollection 2021.

Abstract

Rationale: Dense desmoplastic stroma is a fundamental characteristic of pancreatic ductal adenocarcinoma (PDAC) and comprises up to 80% of the tumor mass. Type I collagen is the major component of the extracellular matrix (ECM), which acts as a barrier to impede the delivery of drugs into the tumor microenvironment. While the strategy to deplete PDAC stroma has failed in clinical trials, normalization of the stroma to allow chemotherapy to kill the tumor cells in the "nest" could be a promising strategy for PDAC therapy. We hypothesize that silencing the poly(rC)-binding protein 2 (αCP2, encoded by the PCBP2 gene) leads to the destabilization and normalization of type I collagen in the PDAC stroma. Methods: We develop a micro-flow mixing method to fabricate a peptide-based core-stabilized PCBP2 siRNA nanocomplex to reverse the accumulation of type I collagen in PDAC tumor stroma. Various in vitro studies were performed to evaluate the silencing activity, cellular uptake, serum stability, and tumor penetration of the PCBP2 siRNA nanocomplex. We also investigated the penetration of small molecules in stroma-rich pancreatic cancer spheroids after the treatment with the PCBP2 siRNA nanocomplex. The anti-tumor activity of the PCBP2 siRNA nanocomplex and its combination with gemcitabine was evaluated in an orthotopic stroma-rich pancreatic cancer mouse model. Results: Silencing the PCBP2 gene using siRNA reverses the accumulation of type I collagen in human pancreatic stellate cells (PSCs) and mouse NIH 3T3 fibroblast cells. The siRNA nanocomplex significantly reduces ECM production and enhances drug penetration through desmoplastic tumor stroma. The combination of gemcitabine with the PCBP2 siRNA nanocomplex markedly suppresses the tumor progression in a desmoplastic PDAC orthotopic mouse model. Conclusion: This approach provides a new therapeutic avenue to improve the antitumor efficacy of PDAC therapies by normalizing tumor stroma using the PCBP2 siRNA nanocomplex.

Keywords: PCBP2; nanocomplex; pancreatic cancer; siRNA; tumor stroma.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antimetabolites, Antineoplastic / pharmacology
  • Carcinoma, Pancreatic Ductal / drug therapy*
  • Carcinoma, Pancreatic Ductal / genetics
  • Carcinoma, Pancreatic Ductal / pathology
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology
  • Gemcitabine
  • Gene Silencing
  • Humans
  • Mice
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / pathology
  • Pancreatic Stellate Cells / drug effects
  • Pancreatic Stellate Cells / metabolism
  • Pancreatic Stellate Cells / pathology
  • RNA, Small Interfering / genetics*
  • RNA-Binding Proteins / antagonists & inhibitors*
  • Stromal Cells / drug effects*
  • Stromal Cells / pathology
  • Tumor Cells, Cultured

Substances

  • Antimetabolites, Antineoplastic
  • PCBP2 protein, human
  • RNA, Small Interfering
  • RNA-Binding Proteins
  • Deoxycytidine
  • Gemcitabine